Inhibikase Therapeutics, Inc.

Direct answer

Inhibikase Therapeutics, Inc. is publicly traded on NASDAQ under the ticker IKT.

Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate...

Can you invest in Inhibikase Therapeutics, Inc.?

Yes. Inhibikase Therapeutics, Inc. trades publicly on NASDAQ as IKT.

View deeper analysis

View detailed research on MarketSnap, including financials, valuation tools, and analyst context.

Open research for Inhibikase Therapeutics, Inc.

Detailed equity research is provided by MarketSnap.